SuperAPI AI Directory
Partner with us中文AI newsFavorites
All toolsAI healthcareRegulatory Copilot

Regulatory Copilot

Assyro's Regulatory Copilot is an AI regulatory submission software for pharmaceutical, biotechnology, and medical device teams, designed to help teams draft submissions faster, detect eCTD deficiencies earlier, and keep submissions audit-ready at all times. It is officially claimed to reduce more than 6 weeks of time and $250,000 in rework costs per regulatory submission cycle, save more than 100 hours per cycle, and shorten review cycles from weeks to days. It provides a shared workspace, supports syncing source files from systems such as SharePoint, Box, and Google Drive, tracks submission readiness in real time, and automatically triggers validation, drafting, routing, and readiness checks at T-30, T-14, and T-3. The workflows align with 21 CFR Part 11, GxP, and EU Annex 11, with role-based access, traceable decisions, and linked submission evidence. It is officially stated to scale submission capacity without expanding staff and to support coordinating multiple projects across jurisdictions. The product is suitable for regulatory affairs, quality, and submission teams. Regarding specific pricing, implementation duration, whether it is compatible with Veeva Vault or Lorenz, whether it supports submissions outside the United States, and whether AI-drafted content is accepted by the FDA, the official materials do not provide clear answers, and it is recommended to learn more through a 30-minute consultation.

Open website

About this tool

Purpose

Regulatory Copilot is AI regulatory submission software launched by Assyro, aimed at pharmaceutical, biotechnology, and medical device teams. According to the official description, it is used to draft submission documents faster, validate content earlier, and keep every submission in an auditable state within a shared workspace.

Key Capabilities

The following capabilities are officially listed:

  • Reduce rework, version drift, and manual status reporting within a unified submission workflow, saving more than 100 hours per cycle.
  • Enable regulatory, quality, and submission teams to review the same version, using shared comments, owners, and traceability to shorten review cycles from weeks to days.
  • Connect SharePoint, Box, Google Drive, and the systems teams already use, keeping version history consistent and reducing handoff errors.
  • Track submission readiness through a real-time view that consolidates validation findings, drafting progress, and risk signals.
  • Automatically trigger workflows such as validation, drafting, routing, and readiness checks at T-30, T-14, and T-3.
  • Scale submission capacity without adding staff through repeatable workflows, validation controls, and auditable execution.
  • Workflows align with 21 CFR Part 11, GxP, and EU Annex 11, providing role-based access, traceable decisions, and linked submission evidence.
  • Coordinate multiple projects through shared workflows, jurisdiction-specific views, and consistent execution across branches and partners.

How to Use

Official materials do not provide specific operating steps or interface descriptions, and only describe the way it works: teams connect source files to Assyro in a shared workspace, the system automatically triggers validation, drafting, routing, and readiness checks at key time points, and displays submission readiness status through a real-time view. It is officially recommended to learn whether it fits your team through a 30-minute consultation.

Applicable Scenarios

Suitable for regulatory affairs, quality, and submission teams in pharmaceutical, biotechnology, and medical device organizations, especially teams hoping to reduce rework, shorten review cycles, remain audit-ready, and coordinate multiple submission projects across jurisdictions. Official materials also mention that it is suitable for lean teams such as a 5-person RA team.

Limitations

The following information is not clearly provided in the official materials: specific pricing and charging model; whether submissions outside the United States are supported; whether it is compatible with Veeva Vault or Lorenz; whether AI-drafted regulatory content is accepted by the FDA; actual implementation duration; specific details of data security. The materials only list these in the form of "questions regulatory leaders often ask before purchasing."Questions are raised, but no answers are given. In addition, the official claims such as "reducing rework time by more than 6 weeks and rework costs by $250,000" and "saving more than 100 hours per cycle" are vendor marketing, and actual results may vary by team and project.

Related tools

Browse category